Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Katsuyuki Fukutake is active.

Publication


Featured researches published by Katsuyuki Fukutake.


British Journal of Haematology | 1995

Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency

Morio Arai; Naomasa Yamamoto; Masaaki Moroi; Noriko Akamatsu; Katsuyuki Fukutake; Kenjiro Tanoue

Platelet glycoprotein VI (GPVI), a 62kD membrane protein, has been identified as one of the platelet receptors for collagen, since GPVI-deficient platelets exhibit abnormal responses to collagen and an abnormal bleeding tendency. We report a female patient with a mild bleeding history whose platelets expressed 10% GPVI of normal platelets. Shape change, aggregation and ATP release of the patients platelets were completely absent in response to 1-5 micrograms/ml collagen but present normally in response to ADP and Ca2+ ionophore A23187. Adhesion of the patients platelets to coated collagen was mildly affected (40-60% of normal platelets) in spite of only 10% expression of GPVI. Flow cytometrical studies revealed that the patients platelets expressed normal amounts of the GPIa/IIa complex. These results suggest that platelet GPVI is less involved in adhesion to collagen than shape change and aggregation induced by collagen.


The New England Journal of Medicine | 2016

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Midori Shima; Hideji Hanabusa; Masashi Taki; Tadashi Matsushita; Tetsuji Sato; Katsuyuki Fukutake; Naoki Fukazawa; Koichiro Yoneyama; Hiroki Yoshida; Keiji Nogami

BACKGROUND In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, and may lead to the formation of anti-factor VIII alloantibodies (factor VIII inhibitors). Emicizumab (ACE910), a humanized bispecific antibody mimicking the cofactor function of factor VIII, was developed to abate these problems. METHODS We enrolled 18 Japanese patients with severe hemophilia A (with or without factor VIII inhibitors) in an open-label, nonrandomized, interindividual dose-escalation study of emicizumab. The patients received subcutaneous emicizumab weekly for 12 weeks at a dose of 0.3, 1.0, or 3.0 mg per kilogram of body weight (cohorts 1, 2, and 3, respectively). The end points were safety and pharmacokinetic and pharmacodynamic profiles. An additional, exploratory end point was the annualized bleeding rate, calculated as 365.25 times the number of bleeding episodes, divided by the number of days in the treatment period as compared with the 6 months before enrollment. RESULTS Emicizumab was associated with neither serious adverse events nor clinically relevant coagulation abnormalities. Plasma concentrations of emicizumab increased in a dose-dependent manner. Activated partial-thromboplastin times remained short throughout the study. The median annualized bleeding rates in cohorts 1, 2, and 3 decreased from 32.5 to 4.4, 18.3 to 0.0, and 15.2 to 0.0, respectively. There was no bleeding in 8 of 11 patients with factor VIII inhibitors (73%) and in 5 of 7 patients without factor VIII inhibitors (71%). Episodic use of clotting factors to control bleeding was reduced. Antibodies to emicizumab did not develop. CONCLUSIONS Once-weekly subcutaneous administration of emicizumab markedly decreased the bleeding rate in patients who had hemophilia A with or without factor VIII inhibitors. (Funded by Chugai Pharmaceutical; JapicCTI number, 121934.).


Journal of Thrombosis and Haemostasis | 2014

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

Steven R. Lentz; Silke Ehrenforth; F. Abdul Karim; Tadashi Matsushita; K. N. Weldingh; J. Windyga; J. N. Mahlangu; A. Weltermann; E. de Paula; Monica Cerqueira; Silva Zupančić-Šalek; O. Katsarou; M. Economou; Laszlo Nemes; Z. Boda; Elena Santagostino; G. Tagariello; Hideji Hanabusa; Katsuyuki Fukutake; M. Taki; Midori Shima; M. Gorska-Kosicka; M. Serban; T. Andreeva; Aleksandar Savic; I. Elezovic; Johnny Mahlangu; W. Tsay; M. Shen; Ampaiwan Chuansumrit

Vatreptacog alfa, a recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions and 99% identity to native FVIIa, was developed to improve the treatment of hemophilic patients with inhibitors.


International Journal of Hematology | 2001

Clinical Trial to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Recombinant Factor VIIa in Japanese Patients With Hemophilia With Inhibitors

Akira Shirahata; Tadashi Kamiya; Junki Takamatsu; Tetsuhito Kojima; Katsuyuki Fukutake; Morio Arai; Hideji Hanabusa; H. Tagami; Akira Yoshioka; Midori Shima; Hiroyuki Naka; Shigeru Fujita; Yoko Minamoto; Junji Kamizono; Hidehiko Saito

A multicenter and open-labeled clinical trial of human recombinant factor VIIa (rFVIIa) was conducted in Japanese patients with severe hemophilia A or B with inhibitors. The trial consisted of 2 parts. In study 1, the pharmacokinetics, pharmacodynamics, and safety of a single dose of 120 μg/kg ofrFVIIa were investigated in 8 patients. In the subsequent study 2, the hemostatic effect and safety ofrFVIIa were evaluated during a 24-week period in 10 patients. In study 1, the mean maximum FVII-coagulant activity (FVII:C) was found to occur after 10 minutes; activity then decreased rapidly and returned to the baseline within 24 hours after a single intravenous infusion of rFVIIa. The mean half-life of FVII:C was 3.5 hours. The activated partial thromboplastin time and prothrombin time in the patients were immediately shortened but returned to the baseline within 24 hours after dosing. In study 2, 86 μg/kg to 120 μg/kg ofrFVIIa (mean, 97 μg/kg) was administered 1 to 85 times to 10 patients. A total of 58.0% (91/157) of bleeding episodes were treated excellently or effectively, with 5 (3.2%) ineffective episodes. There was no apparent trend in the relationship of the hemostatic effect with bleeding sites, mean dose, or number of injections. The efficacy rate, however, was significantly higher (90.0%) in bleeding episodes treated within 3 hours than in those treated at longer intervals (31.0%). No treatment-related adverse events were observed, and there was no evidence of antibody formation to rFVIIa. In conclusion,rFVIIa is an effective and well-tolerated option for treatment of bleeding episodes in hemophilia patients with inhibitors.


Blood | 2014

Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden.

Keiji Nogami; Keiko Shinozawa; Kenichi Ogiwara; Tomoko Matsumoto; Kagehiro Amano; Katsuyuki Fukutake; Midori Shima

Factor V (FV) appears to be pivotal in both procoagulant and anticoagulant mechanisms. A novel homozygote (FVNara), a novel mechanism of thrombosis associated with Trp1920→Arg (W1920R), was found in a Japanese boy and was associated with serious deep vein thrombosis despite a low level of plasma FV activity (10 IU/dL). Activated partial thromboplastin time-based clotting assays and thrombin generation assays showed that FVNara was resistant to activated protein C (APC). Reduced susceptibility of FVaNara to APC-catalyzed inactivation and impaired APC cofactor activity of FVNara on APC-catalyzed FVIIIa inactivation contributed to the APC resistance (APCR). Mixtures of FV-deficient plasma and recombinant FV-W1920R confirmed that the mutation governed the APCR of FVNara. APC-catalyzed inactivation of FVa-W1920R was significantly weakened, by ~11- and ~4.5-fold, compared with that of FV-wild-type (WT) and FVLeiden (R506Q), respectively, through markedly delayed cleavage at Arg506 and little cleavage at Arg306, consistent with the significantly impaired APC-catalyzed inactivation. The rate of APC-catalyzed FVIIIa inactivation with FV-W1920R was similar to that without FV, suggesting a loss of APC cofactor activity. FV-W1920R bound to phospholipids, similar to FV-WT. In conclusion, relative to FVLeiden, the more potent APCR of FVNara resulted from significant loss of FVa susceptibility to APC and APC cofactor activity, mediated by possible failure of interaction with APC and/or protein S.


Thrombosis Research | 1984

A new rapid and simple assay for factor XIII activity using dansylcadaverine incorporation and gel filtration

Yasuharu Nishida; Shojiro Ikematsu; Katsuyuki Fukutake; Michio Fujimaki; Katsuhiro Fukutake; Eizo Kakishita

A new sensitive, reproducible and simple assay for factor XIII activity was developed, in which fluorescent dansylcadaverine (DC) is incorporated into casein and DC-casein is separated from free DC by gel filtration. A good correlation was found between our method and Lorands. The main advantages of our method are: (1) our assay technique is simple with good reproducibility and takes only a couple of hours; (2) the detectable limit of factor XIII activity is about 1% of normal pool plasma, but, if necessary, can be lowered by increasing the sample amount and lengthening the reaction time.


Journal of Thrombosis and Haemostasis | 2015

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.

Johnny Mahlangu; K. N. Weldingh; Steven R. Lentz; Shipra Kaicker; Faraizah Abdul Karim; Tadashi Matsushita; Michael Recht; W. Tomczak; Jerzy Windyga; Silke Ehrenforth; K. Knobe; Ansgar Weltermann; E. de Paula; Monica Cerqueira; Silva Zupančić-Šalek; Olga Katsarou; Marina Economou; Laszlo Nemes; Z. Boda; Elena Santagostino; G. Tagariello; Hideji Hanabusa; Katsuyuki Fukutake; Midori Shima; M. Serban; Ivo Elezovic; Aleksandar Savic; Ming Shen; Ampaiwan Chuansumrit; Pantep Angchaisuksiri

Vatreptacog alfa, a recombinant human factor VIIa (rFVIIa) analog developed to improve the treatment of bleeds in hemophilia patients with inhibitors, differs from native FVIIa by three amino acid substitutions. In a randomized, double‐blind, crossover, confirmatory phase III trial (adept™2), 8/72 (11%) hemophilia A or B patients with inhibitors treated for acute bleeds developed anti‐drug antibodies (ADAs) to vatreptacog alfa.


Thrombosis and Haemostasis | 2016

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Paul Giangrande; Tatiana Andreeva; Pratima Chowdary; Silke Ehrenforth; Hideji Hanabusa; Frank W.G. Leebeek; Steven R. Lentz; Laszlo Nemes; Lone Hvitfeldt Poulsen; Elena Santagostino; Chur Woo You; Wan Hui Ong Clausen; Peter G. Jönsson; Johannes Oldenburg; C. Rothschild; T. Lambert; M. Trossaert; C. Negrier; W. Miesbach; A. Tiede; J. Oldenburg; R. Klamroth; H. Eichler; A. Tosetto; K. Dunsmore; Miguel A. Escobar; J. Wright; Ralph A. Gruppo; G. K. Guron; S. Kearney

Turoctocog alfa pegol (N8-GP) is a novel glycoPEGylated extended half-life recombinant factor VIII (FVIII) product developed for prophylaxis and treatment of bleeds in patients with haemophilia A, to enable higher activity levels with less frequent injections compared with standard FVIII products. This phase III (NCT01480180), multinational, open-label, non-randomised trial evaluated the safety and clinical efficacy of N8-GP when administered for treatment of bleeds and for prophylaxis, in previously treated patients aged ≥12 years with severe haemophilia A. Patients were allocated to receive N8-GP for prophylaxis or on-demand treatment for up to 1.8 years. Patients on prophylaxis were administered one dose of 50 IU/kg of N8-GP every fourth day. Bleeds were treated with doses of 20-75 IU/kg. Total exposure to N8-GP in the trial was 14,114 exposure days (159 patient-years). For the prophylaxis arm (n=175), the median annualised bleeding rate (ABR) was 1.33 (interquartile range, 0.00-4.61), the mean ABR was 3.70 (95 % confidence interval 2.94-4.66) and 70 (40 %) patients had no bleeds during the trial. Across treatment arms, 83.6 % of bleeds resolved with one injection and 95.5 % with up to two injections. N8-GP had a favourable safety profile and was well tolerated. The frequency and types of adverse events reported were as expected in this population. One patient developed inhibitory antibodies against FVIII (≥0.6 Bethesda units [BU]) after 93 N8-GP exposure days. No clinically significant safety concerns were identified and N8-GP was effective for prophylaxis and treatment of bleeds in previously treated patients.


Cancer Genetics and Cytogenetics | 1998

Late Appearance of t(5;12)(q31;p12) in Acute Myeloid Leukemia Associated with Eosinophilia

Naoyuki Yahata; Kazuma Ohyashiki; Junko H. Ohyashiki; Yukihiko Kimura; Keisuke Miyazawa; Atsushi Kodama; Katsuyuki Fukutake; Keisuke Toyama

We report here a case of acute myeloid leukemia with eosinophilia and t(5;12)(q31;p12) at the second relapse. This cytogenetic anomaly is thus associated with one step toward leukemia and eosinophilia.


Blood Advances | 2017

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Midori Shima; Hideji Hanabusa; Masashi Taki; Tadashi Matsushita; Tetsuji Sato; Katsuyuki Fukutake; Ryu Kasai; Koichiro Yoneyama; Hiroki Yoshida; Keiji Nogami

Emicizumab (ACE910), a recombinant humanized bispecific monoclonal antibody, provides factor VIII (FVIII) cofactor bridging function to restore hemostasis in people with hemophilia A. In a phase 1 trial involving 18 Japanese patients with severe hemophilia A, once-weekly subcutaneous administration of emicizumab 0.3, 1, or 3 mg/kg (cohorts 1, 2, and 3, respectively) was well tolerated and substantially reduced annualized bleeding rates (ABRs) in the presence or absence of FVIII inhibitors. The current study represents an open-label, long-term extension of the previously reported 12-week phase 1 study, in which 16 of 18 patients continued to receive emicizumab for up to 33.3 months. Long-term emicizumab treatment was well tolerated, with no thromboembolic events reported and no neutralizing antiemicizumab antibodies developing during the course of the study. Plasma concentrations of emicizumab increased in a dose-proportional manner, with activated partial thromboplastin times remaining short. In cohorts 1, 2, and 3, respectively, median ABRs remained low at 1.4, 0.2, and 0 compared with 4.4, 0, and 0 in the 12-week study. Overall, 8 patients experienced no bleeding events (6 patients with and 2 patients without FVIII inhibitors); dose up-titration resulted in further reduction in ABRs in patients with suboptimal bleeding control; and the episodic use of clotting factors to control bleeding was reduced. In conclusion, long-term emicizumab treatment demonstrated a favorable safety profile with encouraging efficacy, irrespective of the presence of FVIII inhibitors, in patients with hemophilia A. This study was registered at www.clinicaltrials.jp as #JapicCTI-132195.

Collaboration


Dive into the Katsuyuki Fukutake's collaboration.

Top Co-Authors

Avatar

Kagehiro Amano

Tokyo Medical University

View shared research outputs
Top Co-Authors

Avatar

Midori Shima

Nara Medical University

View shared research outputs
Top Co-Authors

Avatar

Morio Arai

Tokyo Medical University

View shared research outputs
Top Co-Authors

Avatar

Masashi Taki

St. Marianna University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Akira Shirahata

University of Occupational and Environmental Health Japan

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Suzuki

Tokyo Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge